Error message

Notice: Undefined offset: 1 in get_navigation_data() (line 70 of /mnt/www/html/pftrumenbastg/docroot/sites/default/modules/custom/pfe_pager/pfe_pager.module).

Dosing & Safety


Ensure your teen completes all recommended doses of TRUMENBA to help protect them against MenB

TRUMENBA follows a 2- or 3-dose schedule1

2-dose schedule for healthy teens
Dose 1

at day 1

Dose 2

6 months after dose 1

  • ACIP* recommends 2 doses for healthy adolescents and young adults2

  • ACIP recommends 3 doses (0, 1-2, 6 months) for people 10 years of age or older who are at increased risk2†

ACIP* recommends 3 doses for persons who are at an increased risk of meningococcal disease or in a MenB outbreak situation2
Dose 1

at day 1

Dose 2

1-2 months after dose 1

Dose 3

6 months after dose 1

*The CDC Advisory Committee on Immunization Practices.

These persons include: persons with persistent complement component deficiencies; persons with anatomic or functional asplenia; microbiologists routinely exposed to isolates of Neisseria meningitidis; persons identified as at increased risk of a MenB disease outbreak.

Discuss with your teen’s health care provider or pharmacist which schedule is appropriate

helpful information
TRUMENBA safety profile

The safety profile of TRUMENBA was assessed in 11 clinical trials that included more than 15,000 adolescents and young adults.1

The safety data demonstrated that TRUMENBA was generally well tolerated.1

The most commonly reported side effects were pain at injection site, fatigue, headache, and muscle pain.1

When TRUMENBA was taken with other vaccines, local adverse reactions did not significantly increase.3,4

map icon

Find TRUMENBA near you

arrowUse my current location Find it!Oops! Please enter a valid ZIP code
locator icon
TRUMENBA offers a vaccine reminder program

Sign up for the TRU NextDose reminder program to help ensure your teen or young adult gets all recommended doses.

Get reminders
  • Trumenba should not be given to anyone with a history of a severe allergic reaction to any component of Trumenba
  • Some individuals with weakened immune systems may have a reduced immune response
  • Persons with certain complement deficiencies and persons receiving treatments such as Soliris® (eculizumab), are at increased risk for invasive disease caused by Neisseria meningitidis group B even with receipt of vaccination with Trumenba
  • Vaccination with Trumenba may not protect all vaccine recipients against N meningitidis group B infections
  • Fainting can occur in association with administration of injectable vaccines, including Trumenba
  • The most common adverse reactions in adolescents and young adults were pain at injection site, fatigue, headache, and muscle pain
  • Data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
  • Tell your health care provider if you are pregnant, or plan to become pregnant
  • Ask your health care provider about the risks and benefits of Trumenba. Only a health care provider can decide if Trumenba is right for you or your child
  • Trumenba is a vaccine indicated for individuals 10 through 25 years of age for active immunization to prevent invasive disease caused by Neisseria meningitidis group B

Patients should always ask their doctors for medical advice about adverse events.

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit or call 1-800-822-7967.

This site is intended only for U.S. residents. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only and is not intended to replace discussions with a healthcare provider.

  1. TRUMENBA [package insert]. Philadelphia, PA: Pfizer Inc.; 2021.
  2. Patton ME, Stephens D, Moore K, et al. Updated recommendations for use of MenB-FHbp serogroup B meningococcal vaccine—Advisory Committee on Immunization Practices, 2016. MMWR Morb Mortal Wkly Rep. 2017;66(19):509-513.
  3. Senders S, Bhuyan P, Jiang Q, et al. Immunogenicity, tolerability and safety in adolescents of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with quadrivalent human papilloma virus vaccine. Pediatr Infect Dis J. 2016;35(5):548-554.
  4. Muse D, Christensen S, Bhuyan P, et al. A phase 2, randomized, active-controlled, observer-blinded study to assess the immunogenicity, tolerability and safety of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with tetanus, diphtheria and acellular pertussis vaccine and serogroup A, C, Y, and W-135 meningococcal conjugate vaccine in healthy US adolescents. Pediatr Infect Dis J. 2016;35(6):673-682.
Back to top